Nuvation Bio Prices Upsized $250 Mln Offering Of Convertible Notes; Stock Down

Nuvation Bio priced an upsized $250 million offering of 0.75% convertible senior notes due 2032, increasing the deal size from the previously announced $200 million. The larger, low-coupon financing provides additional capital for the oncology company, though the headline is primarily a funding update rather than an operating development.

Analysis

Nuvation Bio priced an upsized $250 million offering of 0.75% convertible senior notes due 2032, increasing the deal size from the previously announced $200 million. The larger, low-coupon financing provides additional capital for the oncology company, though the headline is primarily a funding update rather than an operating development.